메뉴 건너뛰기




Volumn 55, Issue 12, 2014, Pages 2754-2760

Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine131-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma

Author keywords

Durable response; Indolent NHL; Quality of life; Radioimmunotherapy; Tositumomab

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; RITUXIMAB; THYROTROPIN; TOSITUMOMAB; TOSITUMOMAB I 131; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

EID: 84919425577     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.894190     Document Type: Article
Times cited : (8)

References (26)
  • 1
    • 0022966964 scopus 로고
    • Follicular lymphoma:prognostic factors for response and survival
    • Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma:prognostic factors for response and survival. J Clin Oncol 1986;4:1470-1480.
    • (1986) J Clin Oncol , vol.4 , pp. 1470-1480
    • Gallagher, C.J.1    Gregory, W.M.2    Jones, A.E.3
  • 2
    • 0037395994 scopus 로고    scopus 로고
    • Overview of non-Hodgkin's lymphoma. Biology, staging and treatment
    • Fisher RI. Overview of non-Hodgkin's lymphoma. Biology, staging and treatment. Semin Oncol 2003;30:3-9.
    • (2003) Semin Oncol , vol.30 , pp. 3-9
    • Fisher, R.I.1
  • 3
    • 14144249536 scopus 로고    scopus 로고
    • Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
    • Horning SJ, Younes A, Jain V, et al. efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719.
    • (2005) J Clin Oncol , vol.23 , pp. 712-719
    • Horning, S.J.1    Younes, A.2    Jain, V.3
  • 4
    • 12944275472 scopus 로고    scopus 로고
    • 131I-tositumomab therapy as initial treatment for follicular lymphoma
    • Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
    • (2005) N Engl J Med , vol.352 , pp. 441-449
    • Kaminski, M.S.1    Tuck, M.2    Estes, J.3
  • 5
    • 0035478728 scopus 로고    scopus 로고
    • Pivotal study of iodine i 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
    • Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
    • (2001) J Clin Oncol , vol.19 , pp. 3918-3928
    • Kaminski, M.S.1    Zelenetz, A.D.2    Press, O.W.3
  • 6
    • 0034017954 scopus 로고    scopus 로고
    • Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
    • Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-1323.
    • (2000) J Clin Oncol , vol.18 , pp. 1316-1323
    • Vose, J.M.1    Wahl, R.L.2    Saleh, M.3
  • 7
    • 2342622100 scopus 로고    scopus 로고
    • Tositumomab and iodine i 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    • Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1469-1479.
    • (2004) J Clin Oncol , vol.22 , pp. 1469-1479
    • Davies, A.J.1    Rohatiner, A.Z.2    Howell, S.3
  • 8
    • 0034662510 scopus 로고    scopus 로고
    • Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
    • Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
    • (2000) Blood , vol.96 , pp. 1259-1266
    • Kaminski, M.S.1    Estes, J.2    Zasadny, K.R.3
  • 9
    • 9744233595 scopus 로고    scopus 로고
    • The radioisotope contributes signif cantly to the activity of radioimmunotherapy
    • Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes signif cantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10: 7792-7798.
    • (2004) Clin Cancer Res , vol.10 , pp. 7792-7798
    • Davis, T.A.1    Kaminski, M.S.2    Leonard, J.P.3
  • 10
    • 33745102812 scopus 로고    scopus 로고
    • Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
    • Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006;94:1770-1776.
    • (2006) Br J Cancer , vol.94 , pp. 1770-1776
    • Buchegger, F.1    Antonescu, C.2    Delaloye, A.B.3
  • 11
    • 79958102423 scopus 로고    scopus 로고
    • Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission
    • Buchegger F, Antonescu C, Helg C, et al. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med 2011; 52:896-900.
    • (2011) J Nucl Med , vol.52 , pp. 896-900
    • Buchegger, F.1    Antonescu, C.2    Helg, C.3
  • 12
    • 32944476224 scopus 로고    scopus 로고
    • Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    • Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573.
    • (2005) J Clin Oncol , vol.23 , pp. 7565-7573
    • Fisher, R.I.1    Kaminski, M.S.2    Wahl, R.L.3
  • 14
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
    • (1999) J Clin Oncol , vol.17 , pp. 1244-1253
    • Cheson, B.D.1    Horning, S.J.2    Coifer, B.3
  • 15
    • 34247561116 scopus 로고    scopus 로고
    • Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    • Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 1009: 1804-1810.
    • (2007) Cancer , vol.1009 , pp. 1804-1810
    • Witzig, T.E.1    Molina, A.2    Gordon, L.I.3
  • 16
    • 18844435974 scopus 로고    scopus 로고
    • Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    • Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185-188.
    • (2005) Cancer Biother Radiopharm , vol.20 , pp. 185-188
    • Wiseman, G.A.1    Witzig, T.E.2
  • 17
    • 0028835315 scopus 로고
    • Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
    • Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-147.
    • (1995) J Clin Oncol , vol.13 , pp. 140-147
    • Johnson, P.W.1    Rohatiner, A.Z.2    Whelan, J.S.3
  • 18
    • 20444411092 scopus 로고    scopus 로고
    • Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    • Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-4582.
    • (2005) Blood , vol.105 , pp. 4576-4582
    • Bennett, J.M.1    Kaminski, M.S.2    Leonard, J.P.3
  • 19
    • 4444326818 scopus 로고    scopus 로고
    • Follicular lymphoma international prognostic index
    • Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
    • (2004) Blood , vol.104 , pp. 1258-1265
    • Solal-Céligny, P.1    Roy, P.2    Colombat, P.3
  • 20
    • 47349105801 scopus 로고    scopus 로고
    • Report of a workshop on malignant lymphoma: A review of molecular and clinical risk Profiling
    • Gleissner B, Küppers R, Siebert R, et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk Profiling. Br J Haematol 2008; 142: 166-178.
    • (2008) Br J Haematol , vol.142 , pp. 166-178
    • Gleissner, B.1    Küppers, R.2    Siebert, R.3
  • 21
    • 70349745593 scopus 로고    scopus 로고
    • Follicular lymphoma international prognostic index 2:A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
    • Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
    • (2009) J Clin Oncol , vol.27 , pp. 4555-4562
    • Federico, M.1    Bellei, M.2    Marcheselli, L.3
  • 22
    • 0037464510 scopus 로고    scopus 로고
    • Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
    • Calle EE, Rodriguez C, Walker-Turmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
    • (2003) N Engl J Med , vol.348 , pp. 1625-1638
    • Calle, E.E.1    Rodriguez, C.2    Walker-Turmond, K.3
  • 23
    • 77749306533 scopus 로고    scopus 로고
    • Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
    • Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-347.
    • (2010) Gut , vol.59 , pp. 341-347
    • Guiu, B.1    Petit, J.M.2    Bonnetain, F.3
  • 24
    • 82955201513 scopus 로고    scopus 로고
    • The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to inf iximab in rheumatoid arthritis:An exploratory study
    • Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to inf iximab in rheumatoid arthritis:An exploratory study. Rheumatology (Oxford) 2011;50:1487-1493.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 1487-1493
    • Klaasen, R.1    Cantaert, T.2    Wijbrandts, C.A.3
  • 25
    • 22544476830 scopus 로고    scopus 로고
    • Obesity and dose individualization in cancer chemotherapy: The role of body surface area and body mass index
    • Portugal RD. Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index. Med Hypotheses 2005;65:748-751.
    • (2005) Med Hypotheses , vol.65 , pp. 748-751
    • Portugal, R.D.1
  • 26
    • 58549091067 scopus 로고    scopus 로고
    • Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA)
    • Hunter RJ, Nano MA, Taker PH, et al. Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
    • (2009) Cancer Treat Rev , vol.35 , pp. 69-78
    • Hunter, R.J.1    Nano, M.A.2    Taker, P.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.